Single-molecule localisation microscopy (SMLM) allows imaging of fluorescently-tagged proteins in live cells with a precision well below that of the diffraction limit. As a single-molecule technique, it has also introduced a new quantitative approach to fluorescence microscopy. In the Part A of this thesis, the design and building of three SMLM instruments, the implementation of a custom-developed image analysis package and the characterisation of the photo-physical properties of the photo-activable fluorescent protein used in this thesis (mEos), are discussed. Then, a new post-processing method for SMLM analysis is characterised: axial optical sectioning of SMLM images is demonstrated by thresholding fitted localisations using their fitted width and amplitude to reject fluorophores that emit from above or below a virtual ?light-sheet?, a thin volume centred on the focal plane of the microscope. This method provides qualitative and quantitative improvements to SMLM. In the Part B of this thesis, SMLM is applied to study T cell activation. Although the T cell receptor plays a key role in immunity, its stoichiometry in the membrane of resting T cells is still a matter of debate. Here, single-molecule counting methods are implemented to compare the stoichiometry of TCRs fused with mEos2 in resting T cells to monomeric and dimeric controls. However, because of the stochasticity of mEos2 photo-physics, results are inconclusive and new counting techniques based on structural imaging are discussed. In addition to TCR triggering, T cells require the co-stimulatory triggering of the CD28 transmembrane receptor to become fully activated. However, some immobilised anti-CD28 antibodies, referred to as super-agonists (SA), can directly activate T cells without triggering the TCR. In this thesis, single-molecule tracking techniques are used to investigate the molecular mechanism of CD28 super-agonism in live T cells. The results indicate that the diffusion of CD28 is slowed by SA binding. This effect is further discussed in light of the kinetic-segregation model proposed for TCR triggering. Quantitative SMLM as implemented and further developed in this work offers new tools to investigate the molecular mechanisms initiating T cell activation, ultimately facilitating the discovery of novel approaches to target these pathways for therapeutic purposes.

La protéine TRAIL (TNF Related Apoptosis Inducing Ligand) suscite un grand intérêt en thérapie anticancéreuse. Contrairement à la plupart des traitements couramment utilisés en clinique, cette protéine induit sélectivement la mort par apoptose de nombreuses cellules cancéreuses. Cette cytokine exerce son activité cytotoxique en se liant à des récepteurs transmembranaires exprimés à la surface de la cellule cible. Par un jeu d’interactions protéiques, la fixation de TRAIL sur ces récepteurs agonistes (TRAIL-R1 et TRAIL-R2) conduit à l’activation de l’apoptose. L’expression de deux récepteurs antagonistes, TRAIL-R3 et TRAIL-R4, par les cellules cancéreuses, permet aux cellules cibles d’échapper à l’apoptose induite par TRAIL. Nous montrons que ces deux récepteurs font intervenir des mécanismes moléculaires distincts. Leur expression pouvant potentiellement représenter un frein à l’utilisation clinique de TRAIL, nous avons étudié l’effet de la surexpression de l’un d’entre eux, TRAIL-R4 sur l’efficacité des stratégies thérapeutiques associant TRAIL aux chimiothérapies conventionnelles. Les résultats obtenus montrent également que la résistance induite par TRAIL-R4 peut être contournée in vitro et in vivo en associant TRAIL à des agents chimiothérapeutiques. D’un point de vue moléculaire, nous avons montré que la sensibilisation à TRAIL 1) implique une augmentation du recrutement et de l’activation de la caspase-8 au sein du DISC de TRAIL, 2) ne nécessite pas la voie mitochondriale, et 3) est négativement régulée de manière coopérative par c-FLIP, un inhibiteur sélectif de la caspase-8. De manière intéressante, comme les anticorps agonistes actuellement testés en clinique, de petits peptides agonistes de TRAIL-R2, développés en collaboration avec une équipe de chimiste, permettent de contourner la résistance induite par TRAIL-R4, offrant des perspectives thérapeutiques intéressantes. Les récepteurs TRAIL-R3 et TRAIL-R4 sont donc des inhibiteurs de TRAIL. Nos travaux démontrent cependant, que les stratégies associant TRAIL à des agents chimiothérapeutiques, ou l'utilisation d'agonistes TRAIL-R2 permet de contourner la résistance induite par les récepteurs antagonistes de TRAIL et donc d’éliminer ces cellules cancéreuses. / TRAIL (TNF Related Apoptosis Inducing Ligand) is a very promising cytokine for cancer therapy. Contrary to current treatments, this protein is able to selectively kill cancer cells, whilst sparing healthy cells. TRAIL induces apoptosis following binding to one of its two different agonistic membrane receptors, TRAIL-R1 and TRAIL-R2. However, expression of one of its two antagonistic receptors, TRAIL-R3 and TRAIL-R4, on cancer cells can impair cancer cell killing by TRAIL. We have shown that these receptors inhibit TRAIL-induced cell death differentially. As these receptors can represent a brake for the use of TRAIL in cancer therapy, we investigated the effect of the expression of one of them, TRAIL-R4 on the efficacy of the different therapeutic strategies associating TRAIL and conventional therapeutic drugs. We show that acquired resistance to TRAIL following expression of TRAIL-R4 can be overcome in vitro and in vivo by combining TRAIL with chemotherapeutic agents. From a molecular point of view, we could demonstrate that sensitization to TRAIL 1) occurs mainly through an increase of caspase-8 recruitment and activation within the TRAIL DISC, 2) is independent of the mitochondrial pathway and 3) is negatively regulated, in a cooperative manner by c-FLIP, a caspase-8 selective inhibitor. Interestingly, like agonistic receptors currently tested in clinic, small agonistic peptides targeting TRAIL-R2, engineered in collaboration with a team of chemists, afford cancer cell killing regardless of TRAIL-R4 expression, providing novel therapeutic perspectives. TRAIL-R3 and TRAIL-R4 should thus be considered as TRAIL inhibitors. Our results demonstrate however that strategies aiming at combining TRAIL with chemotherapeutic agents or the use of TRAIL-R1 or TRAIL-R2 agonists could be effective treatments to eradicate cancer cells that express TRAIL antagonistic receptors.

Chez les rongeurs, la mémoire procédurale est préservée alors que la mémoire « déclarative » est profondément altérée au cours du vieillissement normal ou pathologique.L’injection d’un agoniste partiel des récepteurs 5-HT4 (SL 65.0155. 0.01mg/kg) permet aux rongeurs de récupérer leurs facultés dans une tâche de discrimination olfactive, le labyrinthe olfactif par exemple.L’activation des récepteurs 5-HT4 par un agoniste pourrait être utilisée pour lutter contre les dysfonctionnements mnésiques rencontrés dans certaines pathologies neurodégénératives telle que la maladie d’Alzheimer. L’injection d’un agoniste partiel des récepteurs 5-HT4 (SL 65.0155. 0.01mg/kg) permet aux rongeurs de récupérer leurs facultés dans une tâche de discrimination olfactive, le labyrinthe olfactif par exemple.L’activation des récepteurs 5-HT4 par un agoniste pourrait être utilisée pour lutter contre les dysfonctionnements nésiques rencontrés dans certaines pathologies neurodégénératives telle que la maladie d’Alzheimer. / In normal aging or pathological brain diseases in rodents procedural memory is spared while reference memory is deeply impaired.Injection of a partial selective 5-HT4 agonist (SL65.0155. 0.01mg/kg) enabled complete recovery of association learning performance in an olfactory associative discrimination task, the olfactory tubing maze for exemple.Activation of 5-HT4 receptors by a selective agonist could be useful for the symptomatic treatment of memory dysfunctions related to pathological aging such as Alzheimer’disease.

Made available in DSpace on 2016-05-02T13:55:34Z (GMT). No. of bitstreams: 1 JussaraMaria ReisCalixto-dissertacao.pdf: 678492 bytes, checksum: 69d16272c951188cf230141c93f2978b (MD5) Previous issue date: 2012-11-23 / The objective of this study was to evaluate the effect of arginine and ractopamine on performance, carcass characteristics, lipid profile and liver histological features in growing and finishing pigs. The experimental design was randomized blocks with three treatments, eight repetitions, two animals per experimental unit, for a total of 24 animals (12 barrows and 12 gilts) with 65 days of age and live weight of 32 ± 0,75 quilogramas .The treatments were divided into: T1: control (C) (isocaloric meal and isocaloric), T2: C + 4 ppm of ractopamine and T3: C + 0.8% arginine.The additives ractopamine and arginine were added to the mash feed and these ad libitum for 89 days and 46 days of growth phase and 43 days from the termination phase. On reaching 150 days of age, the animals were slaughtered. We evaluated animal performance (average daily feed intake, average daily gain in weight and feed conversion) weighing the animals at the beginning and end of each phase and the rations offered. At slaughter blood samples were collected for biochemical analysis of lipid profile and liver slices for histological examination. The carcasses were hot and heavy after 24 hours refrigerated, carcass length, backfat thickness and loin eye area, were measured in hot carcass. Ractopamine supplementation improved the average feed intake during the growing phase (P <0.05), and average daily weight gain in crescimemto and finishing phases (P <0.05), without however changing other variables, carcass characteristics (P> 0.05) and lipid profile (P> 0.05). The addition of arginine did not affect performance (P> 0.05), carcass traits (P> 0.05) and lipid profile (P> 0.05).Therefore, it was characterized the beneficial effect of ractopamine on reducing the average consumption ration in the growth phase and increased average daily weight gain and decreased average daily consumption of feed during the finishing phase . / O objetivo deste trabalho foi avaliar o efeito da ractopamina e arginina sobre o desempenho, características de carcaça, perfil lipídico e característica histológica de fígado em suínos em crescimento e terminação. O delineamento experimental foi em blocos casualisados, com três tratamentos, oito repetições, dois animais por unidade experimental, perfazendo um total de 24 animais(12 suínos machos castrados e 12 fêmeas), com 65 dias de idade e peso vivo médio 32 ± 0,75 quilogramas.Os tratamentos foram: T1: controle (C): dieta isoenergética e isocalórica; T2: C + 4 ppm de ractopamina e T3: C + 0,8% de arginina. Os aditivos ractopamina e arginina foram adicionados às rações fareladas e estas fornecidas ad libitum por 89 dias sendo 46 dias da fase crescimento e 43 dias da fase terminação. Ao atingirem 150 dias de idade, os animais foram abatidos. Avaliou-se o desempenho animal (consumo médio diário de ração, ganho médio diário em peso e conversão alimentar) pesando-se os animais no início e final de cada fase e as rações oferecidas. No momento do abate foram colhidas amostras de sangue para análises bioquímicas de perfil lipídico e cortes de fígado para exame histológico. As carcaças foram pesadas quentes e após 24 horas de resfriadas, foram medidos o comprimento de carcaça, espessura de toucinho e a área de olho-de-lombo. A suplementação de ractopamina diminuiu o consumo médio de ração na fase de crescimento e terminação (P<0,05) e o ganho médio diário de peso nas fases de terminação(P<0,05) sem, contudo alterar as outras variáveis como as características de carcaça (P>0,05) e perfil lipídico (P>0,05). A inclusão de arginina não alterou o desempenho (P>0,05), característica da carcaça (P>0,05) e perfil lipídico(P>0,05). Portanto, ficou caracterizado o efeito benéfico da ractopamina sobre a diminuição do consumo médio de ração na fase de crescimento e terminação e o aumento do ganho médio de peso diário na fase de terminação

No description available.

La sclérose en plaques (SEP) est une maladie autoimmune inflammatoire et neurodégénérative du système nerveux central (SNC) chez le jeune adulte résultant d’une altération ciblée de la myéline. Les premiers symptômes de la SEP sont une détérioration cognitive, des vertiges, des douleurs, de la fatigue et une perte de la vision. En condition physiologique, les axones des neurones sont entourés par une gaine de myéline synthétisée par les oligodendrocytes permettant d’accélérer la vitesse de conduction des influx nerveux et de prévenir la mort neuronale. Le modèle expérimental le plus utilisé dans l’étude des mécanismes de la SEP est le modèle de l’encéphalomyélite autoimmune expérimentale (EAE). Après une immunisation contre la glycoprotéine oligodendrocytaire de la myéline 35-55 (MOG35-55), les lymphocytes T Cluster of differentiation (CD)4+ helper (Th)1 et Th17 auto-réactifs induisent une réponse inflammatoire aiguë à la périphérie puis migrent dans le SNC. Ils provoquent alors une réponse inflammatoire dirigée contre la myéline, avec l’intervention descellules myéloïdes. Cela aboutit à la destruction des gaines de myéline diminuant la vitesse de conduction des influx nerveux et une perte axonale, responsables des symptômes mentionnés précédemment. A l’heure actuelle, les traitements contre la SEP peuvent ralentir la progression de la paralysie et diminuer la sévérité ainsi que l’incidence des symptômes diminuant l’inflammation. En revanche, ils n’ont pas d’effets sur les formes progressives de la maladie au cours desquellesles processus neurodégénératifs s’amplifient et dominent ceux de l’inflammation. Il est donc nécessaire de trouver de nouvelles thérapies qui pourront à la fois bloquer l’inflammation et promouvoir la remyélinisation et la neurorégénération. Dans cette optique, de nouvelles cibles thérapeutiques ont émergé pour traiter la SEP : le Vasoactive Intestinal Peptide (VIP), le Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP), l’orexine A, leurs récepteurs ainsi queleurs analogues. En effet, ces neuropeptides présentent des activités anti-inflammatoires et neuroprotectrices. Mes travaux de thèse ont porté sur l’étude des effets d’un agoniste de VPAC2, l’un des récepteurs de VIP et PACAP, et de l’orexine A sur les processus inflammatoires et neurodégénératifs dans le modèle d’EAE ainsi que dans le modèle toxique de la cuprizone (CPZ), induisant la mort des oligodendrocytes matures et la démyélinisation indépendamment des lymphocytes T. Après une immunisation contre la MOG35-55, un traitement systémique de court durée avec BAY55-9837, un agoniste de VPAC2, diminue la sévérité de l’EAE chronique en diminuant la réponse inflammatoire à la périphérie avec une baisse de l’activation lymphocytaire, de l’activité de présentation antigénique des cellules dendritiques et des monocytes ainsi qu’une modulation de la population des lymphocytes T régulateurs. Au niveau de la moelle épinière, l’infiltration descellules immunitaires est moindre et la proportion en microglie/macrophages est plus élevée après traitement par l’agoniste de VPAC2. De plus, BAY55-9837 diminue les processus de démyélinisation et favorise ceux de remyélinisation dans le modèle de la CPZ. En parallèle, l’administration intrapéritonéale à court terme de l’orexine A diminue drastiquement la sévérité de l’EAE chronique. Le traitement ne présente pas d’effet sur la phase d’immunisation de l’EAE mais limite la phase effectriceavec une diminution de l’infiltration des lymphocytes T CD4+, des médiateurs inflammatoires, de la démyélinisation, de l’astrogliose et de l’activation microgliale au niveau du SNC. Par contre, l’administration systémique de l’orexine A ne semble pas avoir d’effet sur les phases de démyélinisation et de remyélinisation au cours du modèle de la CPZ / Multiple sclerosis (MS) is a chronic autoimmune and neurodegenerative disease of the central nervous system (CNS). First MS symptoms are cognitive deterioration, dizziness, pain, fatigue and loss of vision. In physiological condition, the axons of neurons are surrounded by a myelin sheath synthesized by oligodendrocytes to accelerate the conduction velocity of nerve impulses and to prevent neuronal death. The most widely used experimental model of MS is the EAE model. After immunization against MOG35-55, self-reactive Th1 and Th17 cells induce an acute inflammatory response at the periphery and then migrate into the SNC. Then they induce an inflammatory response against myelin, with the intervention of myeloid cells. This results in the destruction of myelin sheaths decreasing the rate of conduction of nerve impulses and axonal loss, responsible for the aforementioned symptoms. Currently, MS treatments can slow the progression of paralysis and decrease the severity and the incidence of symptoms by targeting immune responses. However, these treatments have no effect on the progressive forms of the disease when the neurodegenerative processes amplify and dominate the inflammatory component. It is therefore necessary to find effective therapies that can both block inflammation and also promote remyelination and neuroregeneration.In this context, new therapeutic targets have emerged to treat MS: VIP, PACAP, orexin A, their receptors and their analogs. These neuropeptides have several effects such as anti-inflammatory and neuroprotective activities. My thesis works were focused on the effect of a VPAC2 receptor agonist, one of the three receptors of VIP and PACAP, and orexin A in inflammatory and neurodegenerative processes during MOG35-55-induced EAE model and toxic model using CPZ, which induces mature oligodendrocyte death and demyelination without the influence of lymphocytes.A short term and systemic treatment of BAY55-9837, a VPAC2 agonist, decreases chronic EAE severity with less activation of T lymphocytes and antigen presentation activities of dendritic cells and monocytes as well as Treg population modulation at the periphery. In the CNS, immune cell infiltration is reduced in VPAC2-treated mice compared to PBS-treated mice with an higher microglia/macrophage proportion. Moreover, VPAC2 agonist decreases demyelination processes and enhances remyelination during cuprizone model. In parallel, short term and intraperitoneal administration of orexin A decreases drastically the severity of chronic EAE. Orexin A treatment has no effect on immunization phase of EAE but limits effective phase with a lower infiltration of CD4+ T lymphocytes, inflammatory mediators, demyelination, astrogliosis and microglial activation in the CNS. In contrast, systemic administration of orexin A seems to have no effect during demyelination and remyelination phases in CPZ model.

The thesis is focused on the effect of ghrelin receptor (GHS-R1a) agonists and antagonist on food intake regulation. Ghrelin is the only known periferally produced orexigenic hormone and the only known acylated hormone. GHS-R1a agonists and antagonists could be useful in the treatment of cachexia and obesity, respectively. In the first part of the thesis, newly designed peptidic GHS-R1a agonists were characterized. The agonists were stabilized by replacing octanoylated Ser3 with a fatty acid coupled to diaminopropionic acid by a stable amide bond. Other noncoded amino acids were also incorporated. Ghrelin analogs were modified by replacing the octanoyl group with another fatty acid, incorporation of the second fatty acid or shortening the peptide chain. Most of the tested GHS-R1a agonists were found to possess high affinities for GHS-R1a (Ki = 10-9 - 10-10 nM) and to activate signaling pathways of ghrelin. After subcutaneous (SC) administration to mice, agonists showed significant and prolonged orexigenic effect. In the second part of the thesis, acute and long-term effects of pseudopeptide GHS-R1a agonist JMV1843 were tested in lean C57BL/6 mice. Acute SC administration of JMV1843 to fed mice increased food intake in a dose-dependent manner (ED50 = 1.94 mg/kg). JMV1843 was stable in blood serum in...

The thesis is focused on the effect of ghrelin receptor (GHS-R1a) agonists and antagonist on food intake regulation. Ghrelin is the only known periferally produced orexigenic hormone and the only known acylated hormone. GHS-R1a agonists and antagonists could be useful in the treatment of cachexia and obesity, respectively. In the first part of the thesis, newly designed peptidic GHS-R1a agonists were characterized. The agonists were stabilized by replacing octanoylated Ser3 with a fatty acid coupled to diaminopropionic acid by a stable amide bond. Other noncoded amino acids were also incorporated. Ghrelin analogs were modified by replacing the octanoyl group with another fatty acid, incorporation of the second fatty acid or shortening the peptide chain. Most of the tested GHS-R1a agonists were found to possess high affinities for GHS-R1a (Ki = 10-9 - 10-10 nM) and to activate signaling pathways of ghrelin. After subcutaneous (SC) administration to mice, agonists showed significant and prolonged orexigenic effect. In the second part of the thesis, acute and long-term effects of pseudopeptide GHS-R1a agonist JMV1843 were tested in lean C57BL/6 mice. Acute SC administration of JMV1843 to fed mice increased food intake in a dose-dependent manner (ED50 = 1.94 mg/kg). JMV1843 was stable in blood serum in...

Homotrimeric P2X3 and heteromeric P2X2/3 receptors are present in sensory ganglia and participate in pain perception. In order to develop pharmacological antagonists for these receptors, it is important to clarify which amino acid (AA) residues constitute the agonist binding pouch as well as to learn the stoichiometry of the receptor subunits forming a heteromeric receptor. We expressed the homomeric human (h)P2X3 receptor or its mutants in HEK293 cells and measured the ATP-induced responses by the whole-cell patch-clamp method. For the binding-site mutants, all conserved and some non-conserved AAs in the four nucleotide binding segments (NBSs) of the P2X3 subunit were sequentially replaced by alanine. Especially the positively charged AAs Lys and Arg appeared to be of critical importance for the agonist effects. We concluded that groups of AAs organized in NBSs rather than individual amino acids appear to be responsible for agonist binding at the P2X3 receptor. These NBSs are located at the interface of the three subunits forming a functional receptor. We were also interested to find out, whether two heteromeric receptors (P2X2/3 and P2X2/6), where P2X2 combines with two different partners, have an obligatory subunit stoichiometry of 1:2 or whether the subunit stoichiometry may be variable. For this purpose we used non-functional P2X2, P2X3 and P2X6 subunit-mutants to investigate the composition of heteromeric P2X2/3 and P2X2/6 receptors. The subunit stoichiometry of P2X2/3 and P2X2/6 was found to be 1:2 and 2:1, respectively. Thus, recognitions sites between P2X2 and its partners rather than random association may govern the subunit compositions of the receptor trimers.:Index of contents Introductory remarks „Wissenschaftlicher Anteil des Promovenden an der Publikation“ „Bibliographische Beschreibung“ I. Introduction Pain as a sensory quality Neuronal circuitry for pain processing and sensation in the PNS and CNS Transformation of thermal, mechanical and chemical stimuli into electrical activity by nociceptors; nociceptor-targeted therapeutic approaches Release mechanisms for nucleotides and their fate in the extracellular space Nucleotide receptor-types ATP-sensitive P2 receptors and pain-sensation References II. Scientific background and aims of my thesis ATP binding-sites of P2X3 receptors; subunit composition of P2X2/3 and P2X2/6 heteromeric receptors The aims of the present work III. Publications IV. Summary and conclusions Amino acid residues constituting the agonist binding site of the human P2X3 receptor ATP binding site mutagenesis reveals different subunit stoichiometry of functional P2X2/3 and P2X2/6 receptors „Eigenständigkeitserklärung“ Curriculum vitae Acknowledgements

No description available.